SCNI Scinai Immunotherapeutics Ltd.

Fundamentals / CIK 0001611747 / USD

Scinai Immunotherapeutics Ltd. reported $1.31M in revenue and a net loss of $8.31M for the fiscal year ended December 31, 2025 (up 99.2% year over year), with a -202.3% gross margin and a -575.3% operating margin.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open SCNI in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

5 fiscal years (2021 to 2025), reported in USD.

$5.60M$2.80M$0-$8.17MFY 2021 Net Income: -$8.21M2021FY 2022 Net Income: -$5.80M2022FY 2023 Net Income: -$6.50M2023FY 2024 Revenue: $658KFY 2024 Net Income: $4.80M2024FY 2025 Revenue: $1.31MFY 2025 Net Income: -$8.31M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31 Dec 31 Dec 31
Revenue $1.31M $658K -- -- --
Cost of Revenue $3.96M $1.24M -- -- --
Gross Profit -$2.65M -$580K -- -- --
Research & Development $2.37M $5.53M $5.21M $5.76M $3.25M
Selling, General & Admin $2.52M $2.53M $4.50M $5.30M $7.62M
Total Operating Expenses $4.89M $8.06M $9.71M $11.06M $10.86M
Operating Income -$7.54M -$8.64M -$9.71M -$11.06M -$10.86M
EBITDA -$6.12M -$6.99M -$9.19M -$10.50M -$10.39M
Interest Expense -- -- $343K $351K $336K
Net Income -$8.31M $4.80M -$6.50M -$5.80M -$8.21M
Basic EPS -- -- $0.00 $0.01 -$0.02
Diluted EPS -- -- $0.00 $0.01 -$0.02
Basic Shares Outstanding 9.34B 3.23B 1.56B 754.1M 564.6M
Diluted Shares Outstanding 9.34B 3.23B 1.56B 754.1M 564.6M

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2023-03-31 2022-03-31
Research & Development $2.00M $1.16M
Operating Income -$3.19M -$2.62M
EBITDA -$3.05M -$2.48M
Net Income -$3.52M -$2.48M
Basic EPS -$0.00 -$0.00
Diluted EPS -$0.00 -$0.00
Basic Shares Outstanding 1.30B 744.7M
Diluted Shares Outstanding 1.30B 744.7M

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31 Dec 31 Dec 31 Dec 31
Cash & Cash Equivalents $1.66M $1.96M $4.87M $14.07M $17.37M
Cash & Short-Term Investments $1.66M $1.96M $4.87M $14.07M $17.37M
Accounts Receivable, Net $73K $83K -- -- --
Other Current Assets -- -- $437K $155K --
Total Current Assets $2.05M $2.39M $5.45M $14.37M $17.84M
Property, Plant & Equipment, Net $7.79M $9.19M $10.82M $11.24M $12.39M
Total Non-Current Assets $9.57M $11.06M $12.03M $12.70M $14.19M
Total Assets $11.63M $13.45M $17.47M $27.07M $32.04M
Accounts Payable $407K $376K $535K $716K $999K
Short-Term Debt -- -- -- $382K $375K
Deferred Revenue (Current) $90K $225K -- -- --
Total Current Liabilities $1.58M $1.81M $1.78M $2.34M $2.44M
Total Non-Current Liabilities $1.94M $1.67M $20.26M $26.49M $28.61M
Total Liabilities $3.52M $3.47M $22.04M $28.83M $31.05M
Total Debt (incl. Leases) $1.96M $1.83M $1.19M $764K $1.82M
Retained Earnings -$125.8M -$117.5M -$122.3M -$115.8M -$110.0M
Accumulated Other Comp. Income -$1.74M -$1.74M -$1.74M -$2.01M -$2.06M
Total Stockholders' Equity $8.10M $9.98M -$4.57M -$1.76M $982K
Total Equity $8.10M $9.98M -$4.57M -$1.76M $982K

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2025-12-31 2024-12-31 2023-12-31 2023-03-31 2022-12-31 2021-12-31
Cash & Cash Equivalents $1.66M $1.96M $4.87M $10.80M $14.07M $17.37M
Cash & Short-Term Investments $1.66M $1.96M $4.87M $10.80M $14.07M $17.37M
Accounts Receivable, Net $73K $83K -- -- -- --
Other Current Assets -- -- $437K -- $155K --
Total Current Assets $2.05M $2.39M $5.45M $11.04M $14.37M $17.84M
Property, Plant & Equipment, Net $7.79M $9.19M $10.82M $10.82M $11.24M $12.39M
Total Non-Current Assets $9.57M $11.06M $12.03M $12.25M $12.70M $14.19M
Total Assets $11.63M $13.45M $17.47M $23.29M $27.07M $32.04M
Accounts Payable $407K $376K $535K $1.31M $716K $999K
Short-Term Debt -- -- -- -- $382K $375K
Deferred Revenue (Current) $90K $225K -- -- -- --
Total Current Liabilities $1.58M $1.81M $1.78M $2.58M $2.34M $2.44M
Total Non-Current Liabilities $1.94M $1.67M $20.26M $25.52M $26.49M $28.61M
Total Liabilities $3.52M $3.47M $22.04M $28.10M $28.83M $31.05M
Total Debt (incl. Leases) $1.96M $1.83M $1.19M $420K $764K $1.82M
Retained Earnings -$125.8M -$117.5M -$122.3M -$119.3M -$115.8M -$110.0M
Accumulated Other Comp. Income -$1.74M -$1.74M -$1.74M -$1.89M -$2.01M -$2.06M
Total Stockholders' Equity $8.10M $9.98M -$4.57M -$4.81M -$1.76M $982K
Total Equity $8.10M $9.98M -$4.57M -$4.81M -$1.76M $982K

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31 Dec 31 Dec 31
Net Income -$8.31M $4.80M -$6.50M -$5.80M -$8.21M
Depreciation & Amortization $1.42M $1.65M $514K $562K $471K
Stock-Based Compensation $303K $682K $1.14M $1.60M $2.76M
Change in Receivables $10K -$83K -- -- --
Change in Payables $31K -$156K -$150K -$175K $3.0K
Operating Cash Flow -$6.03M -$6.33M -$9.38M -$7.26M -$7.43M
Capital Expenditure -$24K -$12K -$637K -$836K -$139K
Free Cash Flow -$6.05M -$6.35M -$10.02M -$8.10M -$7.57M
Investing Cash Flow -$24K -$12K -$637K -$836K -$139K
Common Stock Issued -- $2.00M $139K $932K $21.43M
Financing Cash Flow $5.77M $3.44M $1.09M $6.78M $21.43M
Net Change in Cash -$284K -$2.92M -$9.21M -$3.30M $14.44M

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2023-03-31 2022-03-31
Net Income -$3.52M -$2.48M
Depreciation & Amortization $138K $134K
Stock-Based Compensation $252K $485K
Change in Payables $629K $311K
Operating Cash Flow -$3.06M -$1.10M
Capital Expenditure -$6.0K -$521K
Free Cash Flow -$3.06M -$1.63M
Investing Cash Flow -$6.0K -$521K
Net Change in Cash -$3.29M -$1.99M

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31 Dec 31 Dec 31
Gross Margin -202.3% -88.1% -- -- --
Operating Margin -575.3% -1312.8% -- -- --
Net Profit Margin -633.6% 728.9% -- -- --
Return on Equity (ROE) -102.5% 48.1% -- -- -835.6%
Return on Assets (ROA) -71.5% 35.7% -37.2% -21.4% -25.6%
Current Ratio 1.30x 1.32x 3.06x 6.15x 7.30x
Quick Ratio 1.09x 1.13x 2.74x 6.02x 7.11x
Debt to Equity 0.24x 0.18x -- -- 1.85x
Revenue Growth (YoY) +99.2% -- -- -- --
Net Income Growth (YoY) -273.2% -- -- -- --
EPS Growth (YoY) -- -- -60.0% -- --

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2023-03-31 2022-03-31
Current Ratio 4.28x --
Quick Ratio 4.19x --
Source: SEC EDGAR CompanyFacts (CIK 0001611747) · from December 31, 2021 Data through December 31, 2025 · synced Nov 21, 2026, 05:15 UTC · Open in terminal